Health Care [ 6/12 ] | Biotechnology [ 43/73 ]
NASDAQ | Common Stock
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies to treat cancer and infectious diseases in Germany.
The company develops BNT111, which is in Phase 2 clinical trial for advance melanoma; BNT113, which is in Phase 2 clinical trial to treat head and neck squamous cell carcinoma; BNT116, which is in Phase I clinical trial for non-small cell lung cancer; BNT142, which is in phase 1/2 clinical trial for multiple solid tumors; BNT151, which is in phase 1/2 clinical trial for solid tumors; BNT152+BNT153, which is in phase 1 clinical trial for solid tumors; and BNT122/RO7198457, which is in Phase 2 clinical trial to treat adjuvant high-risk muscle-invasive urothelial carcinoma, colorectal cancer, pancreatic ductal adenocarcinoma, advance melanoma, as well as in phase 1a/1b clinical trial for advanced/metastatic solid tumors.
It also develops BNT211, which is in phase 1 clinical trial to treat CLDN6+ solid tumors; BNT221, phase 1 clinical trial for the treatment of cancer; BNT311/GEN1046 (acasunlimab), which is in phase 3 clinical trial for solid tumors; BNT312/GEN1042, which is in phase 1/2 and 1 clinical trial to treat solid tumors; BNT314/GEN1059, which is in Phase 1/2 clinical trial for advanced or metastatic solid tumors; BNT315/GEN1055, which is in phase 1/2 clinical trial for advanced solid tumors; BNT317, which is in phase 1 clinical trial for advanced solid tumors; BNT327, which is in phase 1/2, 2, and 3 clinical trial to treat small cell lung cancer, advanced/metastatic tnbc, neuroendocrine neoplasm, malignant mesothelioma, EGFR-mutant non-squamous, hepatocellular carcinoma, and advanced solid tumors; and BNT316/ONC-392, which is in phase 1/2, 2, and 3 clinical trial to treat metastatic, non-small cell lung cancer, platinum-resistant ovarian cancer, metastatic castration resistant prostate cancer, and advanced or metastatic solid tumor.
BioNTech SE was incorporated in 2008 and is headquartered in Mainz, Germany.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Aug 4, 25 | -1.60 Increased by +52.38% | -1.41 Decreased by -13.48% |
| May 16, 25 | -1.82 Decreased by -29.13% | -2.35 Increased by +22.42% |
| Mar 10, 25 | 1.08 Decreased by -43.16% | 0.48 Increased by +126.56% |
| Nov 4, 24 | 0.88 Increased by +31.34% | -1.70 Increased by +151.76% |
| Aug 5, 24 | -3.36 Decreased by -325.32% | -2.02 Decreased by -66.34% |
| May 6, 24 | -1.41 Decreased by -168.78% | -1.17 Decreased by -20.51% |
| Mar 20, 24 | 1.90 Decreased by -79.48% | 2.42 Decreased by -21.49% |
| Nov 6, 23 | 0.67 Decreased by -90.40% | -0.10 Increased by +770.00% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Jun 30, 25 | 260.80 M Increased by +101.62% | -386.60 M Increased by +52.38% | Decreased by -148.24% Increased by +76.38% |
| Mar 31, 25 | 182.80 M Decreased by -3.13% | -415.80 M Decreased by -31.96% | Decreased by -227.46% Decreased by -36.22% |
| Dec 31, 24 | 1.19 B Decreased by -19.54% | 259.50 M Decreased by -43.33% | Increased by +21.81% Decreased by -29.57% |
| Sep 30, 24 | 1.24 B Increased by +39.04% | 195.46 M Increased by +21.70% | Increased by +15.70% Decreased by -12.47% |
| Jun 30, 24 | 129.35 M Decreased by -22.87% | -811.89 M Decreased by -326.41% | Decreased by -627.66% Decreased by -452.83% |
| Mar 31, 24 | 188.70 M Decreased by -85.22% | -315.10 M Decreased by -162.74% | Decreased by -166.98% Decreased by -524.60% |
| Dec 31, 23 | 1.48 B Decreased by -65.43% | 457.90 M Decreased by -79.91% | Increased by +30.96% Decreased by -41.87% |
| Sep 30, 23 | 895.30 M Decreased by -74.13% | 160.60 M Decreased by -91.00% | Increased by +17.94% Decreased by -65.22% |